share_log

Goldman Sachs Maintains Neutral on Revance Therapeutics, Raises Price Target to $9

Moomoo 24/7 ·  Mar 1 06:04

Goldman Sachs analyst Chris Shibutani maintains Revance Therapeutics (NASDAQ:RVNC) with a Neutral and raises the price target from $8 to $9.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment